WALTHAM, Mass., Dec. 21 /PRNewswire-FirstCall/ -- On December 16, 2005 Inverness Medical Innovations , a leading manufacturer and marketer of rapid diagnostic products for the consumer and professional markets, announced that its wholly owned subsidiary, Binax, Inc. had obtained FDA clearance for inclusion of an avian influenza claim for its BinaxNOW A(R) Influenza A & B Test. Inverness recognizes that the title of the announcement and the description of the new claim may be interpreted to mean that the test has been demonstrated to work with human clinical specimens.
Due to the scarcity of avian influenza in the human population, clinical specimens are not broadly available to the medical diagnostics test industry. As with other flu tests on the market, the ability of the BinaxNOW A(R) Influenza A&B Test to detect influenza A virus in human samples from patients infected with the H5N1 virus has not been established. However, in a recent analytical study, Binax demonstrated the reactivity of the BinaxNOW A(R) Influenza A & B Test with two isolates of H5N1 influenza that had been cultured in mammalian cells. These isolates have been added to the analytical reactivity section of its product labelling.
About Inverness Medical Innovations, Inc.
Inverness Medical Innovations is a leading global developer of in vitro diagnostic products and is presently exploring new opportunities for its lateral flow immunoassay and other proprietary technologies in a variety of professional diagnostic and consumer-oriented applications, including immunodiagnostics with a focus on cardiology, infectious disease and women’s health. Inverness’ new product development efforts, as well as its position as a leading supplier of consumer pregnancy and fertility/ovulation tests and rapid point-of-care diagnostics, are supported by the strength of its intellectual property portfolio. The Company is headquartered in Waltham, Massachusetts.
For more information about Inverness Medical Innovations, please visit our website at http://www.invernessmedical.com.
For more information about Binax and its NOW(R) brand of rapid in vitro diagnostic tests, please visit http://www.Binax.com.
Contact: Doug Guarino, Director of Corporate Relations 781 647 3900
Inverness Medical Innovations
CONTACT: Doug Guarino, Director of Corporate Relations +1-781-647-3900
Web site: http://www.invernessmedical.com//